| Drug Type Small molecule drug | 
| Synonyms Hemi L-glutarate salt of 7-[(3R,4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5- dihydro-pyrrolo [3,2-d] pyrimidin-4-one, LR 09, LR-09 + [1] | 
| Target | 
| Action inhibitors | 
| Mechanism PNP inhibitors(Purine nucleoside phosphorylase inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Leukemia | Preclinical | Canada  | 01 Sep 2025 | |
| Acute Lymphoblastic Leukemia | Preclinical | Switzerland  | 14 Dec 2022 | 





